<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pentosan polysulfate sodium: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pentosan polysulfate sodium: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pentosan polysulfate sodium: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10964" href="/d/html/10964.html" rel="external">see "Pentosan polysulfate sodium: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57397443"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elmiron</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867207"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Elmiron</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F182912"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Urinary</li></ul></div>
<div class="block doa drugH1Div" id="F182890"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fef1f7c-57c6-4226-b257-b8b6de839621">Interstitial cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial cystitis:</b>
<b>Oral:</b> 100 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Patients should be re-evaluated after 3 months; therapy may continue for an additional 3 months if there has been no improvement and if there are no therapy-limiting side effects. <b>The risks and benefits of continued use beyond 6 months in patients who have not responded is not yet known</b>.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990786"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987992"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, hepatic impairment may affect pharmacokinetics; use with caution.</p></div>
<div class="block doe drugH1Div" id="F182891"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F7272270"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fef1f7c-57c6-4226-b257-b8b6de839621">Interstitial cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial cystitis:</b> Adolescents ≥16 years: Oral: Refer to adult dosing.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51152735"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51152736"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, hepatic impairment may affect pharmacokinetics; use with caution.</p></div>
<div class="block adr drugH1Div" id="F182863"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (4%), diaphoresis (1%), skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (≤1%), increased lactate dehydrogenase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), diarrhea (4%), dyspepsia (1% to 2%), nausea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Rectal hemorrhage (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function (1%), increased serum alkaline phosphatase (≤1%), increased serum transaminase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (≤2%), dizziness (1%), emotional lability (≤2%), headache (3%), insomnia (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses, pruritus, skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, colitis, constipation, esophagitis, flatulence, gastritis, gingival hemorrhage, oral mucosa ulcer, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukopenia, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia, conjunctivitis, optic neuritis, retinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, epistaxis, pharyngitis, rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Ophthalmic: Macular degeneration (McGwin 2022), maculopathy (including pigmentary maculopathy with long-term use) (Pearce 2018; McGwin 2022), retinal pigment changes, retinal toxicity (including retinal dystrophy and injury) (McGwin 2022)</p></div>
<div class="block coi drugH1Div" id="F182875"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to pentosan polysulfate sodium, structurally related compounds (low-molecular-weight heparins or heparin), or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of any macular pathology.</p></div>
<div class="block war drugH1Div" id="F182860"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Pentosan polysulfate is a low-molecular weight heparin-like compound with anticoagulant and fibrinolytic effects, therefore, bleeding complications (such as ecchymosis, epistaxis, and gum bleeding) may occur. Patients undergoing invasive procedures or having signs or symptoms of underlying coagulopathies or other increased risk of bleeding (eg, receiving heparin, warfarin, thrombolytics, NSAIDs, or high dose aspirin) should be evaluated prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Pigmentary changes in the retina, including pigmentary maculopathy, have been reported with long-term use (≥3 years), but may occur with a shorter duration of use; cumulative dose may be a risk factor. Use with caution in patients with retinal pigment changes from other causes. Obtain a detailed ophthalmologic history prior to initiation of therapy; consider genetic testing in patients with a family history of hereditary pattern dystrophy. Retinal exams, including ocular coherence tomography and auto-fluorescence imaging, are recommended for all patients within 6 months of initiating therapy and periodically during treatment. A comprehensive baseline retinal exam, including color fundoscopic photography, ocular coherence tomography, and auto-fluorescence imaging, is recommended before initiating therapy in patients with preexisting ophthalmologic conditions. Risks and benefits of continuing treatment should be reevaluated if pigmentary changes in the retina develop; changes may be irreversible. Follow-up retinal examinations should be continued since retinal and vision changes may progress after discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aneurysm: Carefully evaluate patients with aneurysm before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Carefully evaluate patients with hemophilia and/or thrombocytopenia before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Carefully evaluate patients with gastrointestinal ulcerations, polyps, and/or diverticula before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heparin-induced thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Safety and efficacy have not been established in children &lt;16 years of age.</p></div>
<div class="block foc drugH1Div" id="F57397444"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elmiron: 100 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F182856"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F182877"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Elmiron Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $13.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867208"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elmiron: 100 mg</p></div>
<div class="block adm drugH1Div" id="F182872"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with water 1 hour before or 2 hours after meals.</p></div>
<div class="block admp drugH1Div" id="F52613053"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with water 1 hour before or 2 hours after meals.</p></div>
<div class="block meg drugH1Div" id="F55678026"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Elmiron: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F020193s015lbl.pdf%23page%3D11&amp;token=AcUYlIkKjZBm4PTziTgHNN2Yy6bV7w6iILg2GsXl%2FkwXogTrf7hxOMqGY%2F3koUBwnsDj%2FxLzHPqRR7ogaxbsSXRVB2h6CbYU61sjnGj%2F7qCvQ2rFUloCZxvTbMuDLyNL&amp;TOPIC_ID=9755" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020193s015lbl.pdf#page=11</a></p></div>
<div class="block use drugH1Div" id="F182871"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Interstitial cystitis:</b> Relief of bladder pain or discomfort due to interstitial cystitis</p></div>
<div class="block mst drugH1Div" id="F182917"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pentosan may be confused with pentostatin</p>
<p style="text-indent:-2em;margin-left:4em;">Elmiron may be confused with Imuran</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299850"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F182865"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Pentosan Polysulfate Sodium may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Pentosan Polysulfate Sodium may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F182878"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">No adverse events were noted in animal reproduction studies; however, reversible limb bud abnormalities were noted during in vitro animal studies. Use with caution and only if clearly needed during pregnancy. Based on limited data, pentosan polysulfate does not appear to cross the placenta.</p></div>
<div class="block brc drugH1Div" id="F20617638"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if pentosan polysulfate sodium is excreted in breast milk. The manufacturer recommends that caution be exercised when administering pentosan polysulfate sodium to nursing women.</p></div>
<div class="block mop drugH1Div" id="F54675405"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Perform retinal exams for all patients within 6 months of initiating therapy and periodically during treatment; baseline retinal exam in patients with preexisting ophthalmologic conditions before initiating therapy.</p></div>
<div class="block pha drugH1Div" id="F182859"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Although pentosan polysulfate sodium is a low-molecular weight heparinoid, it is not known whether these properties play a role in its mechanism of action in treating interstitial cystitis; the drug appears to adhere to the bladder wall mucosa where it may act as a buffer to protect the tissues from irritating substances in the urine.</p></div>
<div class="block phk drugH1Div" id="F182874"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: ~6% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic and splenic via partial desulfation; partial depolymerization occurs in the renal parenchyma; saturable </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 20-27 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2 hours (range: 0.6-120 hours)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (58% to 84%, as unchanged drug); urine (6%, primarily as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F182879"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Accyst | Elmiron</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cystosan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Elmiron | Mentosanil | Pentodol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Comfora</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cystopen | For ic</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fibrase</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Elmiron | Gagron | Jelmiron | Penpol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Elmiron</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Armiro | Elmiron</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Elmiron | Urosan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Elmiron-100 MG (pentosan polysulfate sodium) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2021.</div>
</li>
<li>
<div class="reference">
                  Elmiron (pentosan polysulfate sodium) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2436327">
<a name="2436327"></a>Forestier F, Fischer AM, Daffos F, et al, “Absence of Transplacental Passage of Pentosan Polysulfate During Mid Trimester of Pregnancy,” <i>Thromb Haemost</i>, 1986, 15;56(3):247-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentosan-polysulfate-sodium-drug-information/abstract-text/2436327/pubmed" id="2436327" target="_blank">2436327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34792558">
<a name="34792558"></a>McGwin G Jr, MacLennan P, Owsley C. Association between pentosan polysulfate sodium and retinal disorders. <i>JAMA Ophthalmol</i>. 2022;140(1):37-42. doi:10.1001/jamaophthalmol.2021.4778<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentosan-polysulfate-sodium-drug-information/abstract-text/34792558/pubmed" id="34792558" target="_blank">34792558</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. <i>Ophthalmology</i>. 2018;125(11):1793-1802. doi: 10.1016/j.ophtha.2018.04.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentosan-polysulfate-sodium-drug-information/abstract-text/29801663/pubmed" id="29801663" target="_blank">29801663</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  UK Drug Safety update. Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy. Available at <a href="https://www.gov.uk/drug-safety-update/elmiron-pentosan-polysulfate-sodium-rare-risk-of-pigmentary-maculopathy" target="_blank">https://www.gov.uk/drug-safety-update/elmiron-pentosan-polysulfate-sodium-rare-risk-of-pigmentary-maculopathy</a>. Accessed October 2, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9755 Version 157.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
